Scarica l'app Stockscreener
8.27
0.73%
0.06
Dopo l'orario di chiusura:
8.27
Precedente Chiudi:
$8.21
Aprire:
$8.26
Volume 24 ore:
127.66K
Relative Volume:
0.46
Capitalizzazione di mercato:
$402.20M
Reddito:
$62.02M
Utile/perdita netta:
$-45.65M
Rapporto P/E:
0.728
EPS:
11.36
Flusso di cassa netto:
$-9.60M
1 W Prestazione:
-4.39%
1M Prestazione:
+2.10%
6M Prestazione:
-12.58%
1 anno Prestazione:
-16.04%
Intervallo 1D:
$8.139
$8.30
Intervallo di 1 settimana:
$8.139
$8.65
Portata 52W:
$7.44
$11.71
Theravance Biopharma Inc Stock (TBPH) Company Profile
Nome
Theravance Biopharma Inc
Settore
Industria
Telefono
650-808-6000
Indirizzo
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-11-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-09-15 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-08-25 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2021-08-24 | Downgrade | Cowen | Outperform → Market Perform |
| 2020-10-14 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-07 | Iniziato | JP Morgan | Overweight |
| 2020-06-15 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-05-13 | Iniziato | Cowen | Outperform |
| 2020-01-08 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-06 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2019-10-29 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-29 | Ripresa | Piper Jaffray | Overweight |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-06-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-05-11 | Reiterato | Needham | Buy |
| 2016-12-21 | Iniziato | Needham | Buy |
| 2016-11-03 | Iniziato | Piper Jaffray | Overweight |
| 2016-10-12 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2016-08-03 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2016-06-20 | Iniziato | Guggenheim | Buy |
| 2016-06-20 | Reiterato | Leerink Partners | Outperform |
| 2016-05-12 | Iniziato | Leerink Partners | Outperform |
| 2016-05-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2015-02-03 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
Mostra tutto
Theravance Biopharma Inc Borsa (TBPH) Ultime notizie
Theravance Biopharma (TBPH) Scheduled to Post Earnings on Tuesday - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Theravance Biophar - GuruFocus.com
(TBPH) Proactive Strategies - Stock Traders Daily
Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by SG Americas Securities LLC - MarketBeat
When (TBPH) Moves Investors should Listen - Stock Traders Daily
Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024 - StockTitan
Q3 EPS Estimate for Theravance Biopharma Boosted by Analyst - MarketBeat
Brokerages Set Theravance Biopharma, Inc. (NASDAQ:TBPH) PT at $13.75 - Defense World
What is Zacks Research's Estimate for TBPH Q4 Earnings? - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Average Rating of "Hold" by Analysts - MarketBeat
The Manufacturers Life Insurance Company Decreases Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance study shows YUPELRI improves COPD lung function By Investing.com - Investing.com Australia
Theravance Biopharma (NASDAQ:TBPH) Shares Pass Below 200 Day Moving AverageHere's What Happened - MarketBeat
Theravance study shows YUPELRI improves COPD lung function - Investing.com
Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease - StockTitan
Where are the Opportunities in (TBPH) - Stock Traders Daily
Dimensional Fund Advisors LP Has $2.80 Million Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
Theravance Biopharma (STU:0TB) Price-to-Operating-Cash-Flow : (As of Oct. 10, 2024) - GuruFocus.com
Squarepoint Ops LLC Takes $986,000 Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
Bank of Montreal Can Raises Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Stock Holdings Lifted by Marshall Wace LLP - MarketBeat
(TBPH) Pivots Trading Plans and Risk Controls - Stock Traders Daily
XTX Topco Ltd Purchases New Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y - MSN
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Rhumbline Advisers Sells 15,095 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) - Defense World
An Analysis of Theravance Biopharma Inc (TBPH)’s Potential Price Growth - Knox Daily
Theravance Biopharma settles patent litigation with Qilu Pharmaceutical - Investing.com
Baupost Group LLC MA Decreases Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) Given “Buy” Rating at HC Wainwright - Defense World
H.C. Wainwright maintains Buy rating on Theravance Biopharma shares By Investing.com - Investing.com Canada
Theravance Biopharma (NASDAQ:TBPH) Earns Buy Rating from HC Wainwright - MarketBeat
Unveiling 4 Analyst Insights On Theravance Biopharma - Benzinga
How To Trade (TBPH) - Stock Traders Daily
Leerink Partners gives a Market perform recommendation for Theravance Biopharma Inc (TBPH) - Knox Daily
Seth Klarman's Complete Exit from Theravance Biopharma Inc - Yahoo Finance
Theravance Biopharma Outlines Growth Strategy at Investment Conference - TipRanks
Here's Why We're Not At All Concerned With Theravance Biopharma's (NASDAQ:TBPH) Cash Burn Situation - Yahoo Finance
Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Theravance Biopharma Inc (TBPH) receives a Market perform rating from Leerink Partners - Knox Daily
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Rating of “Hold” by Analysts - Defense World
Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $13.75 Consensus Target Price from Analysts - MarketBeat
Q3 2024 EPS Estimates for Theravance Biopharma, Inc. (NASDAQ:TBPH) Reduced by Analyst - MarketBeat
Theravance Biopharma (NASDAQ:TBPH) Shares Pass Below 50-Day Moving Average of $8.90 - MarketBeat
Theravance Biopharma, Inc. (NASDAQ:TBPH) to Post Q4 2025 Earnings of $0.41 Per Share, Zacks Research Forecasts - Defense World
Zacks Research Brokers Increase Earnings Estimates for Theravance Biopharma, Inc. (NASDAQ:TBPH) - MarketBeat
Theravance Biopharma to Participate in an Upcoming Investor Conference - Citizentribune
Theravance Biopharma (NASDAQ:TBPH) Stock Crosses Below Fifty Day Moving Average of $8.90 - Defense World
TBPH Stock Earnings: Theravance Biopharma Beats EPS, Misses Revenue for Q2 2024 - MSN
Leerink Partners Downgrades Theravance Biopharma Inc (TBPH) to a Market perform from an Outperform - Knox Daily
Theravance Biopharma Inc Azioni (TBPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Theravance Biopharma Inc Azioni (TBPH) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS |
Jul 10 '24 |
Sale |
9.00 |
4,000 |
36,000 |
335,965 |
| Samaha Eli | 10% Owner |
May 01 '24 |
Buy |
8.75 |
1,499,124 |
13,117,335 |
8,511,350 |
| Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS |
Feb 22 '24 |
Sale |
8.71 |
1,254 |
10,922 |
311,733 |
| Farnum Rhonda | SVP, COMM & MEDICAL AFFAIRS |
Nov 21 '23 |
Sale |
10.29 |
1,378 |
14,180 |
331,206 |
| GRAHAM RICHARD A | SVP, RESEARCH & DEVELOPMENT |
Nov 14 '23 |
Sale |
10.22 |
2,482 |
25,366 |
346,839 |
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):